A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose ExpansionStudy of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patientswith Advanced Cancers Associated with Expression of Delta-Like CanonicalNotch Ligand 3 (DLL3) Who Have

Project: Research project

Project Details

Description

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have
StatusActive
Effective start/end date5/1/214/30/26

Funding

  • HARPOON THERAPEUTICS, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.